The present invention discloses a transparent rubber-modified monovinylidene aromatic resin. The rubber-modified monovinylidene aromatic resin comprises: a dispersed rubber particle (A) and a continuous phase matrix copolymer (B). The surface of the molding has a maximum height difference (&Dgr;Hmax) of less than 3,200 Å, and an average height difference (&Dgr;Have) of less than 2,000 Å when measured with a surface profiler. The average ratios of major diameter to minor diameter of said rubber particles before and after annealing at 120° C. for 40 mins are A1 and A2 respectively, and the ratio of A1/A2 ranges form 1.08 to 2.35.
Process for the production of a transparent rubber-modified monovinylidene aromatic resin
申请人:Hsu Ray-Hsi
公开号:US20060142487A1
公开(公告)日:2006-06-29
The present invention discloses a process for the production of a transparent rubber-modified monovinylidene aromatic resin. The rubber-modified monovinylidene aromatic resin comprises: a dispersed rubber particle (A) and a continuous phase matrix copolymer (B). The surface of the molding has a maximum height difference (ΔHmax) of less than 3,200 Å, and an average height difference (ΔHave) of less than 2,000 Å when measured with a surface profiler. The average ratios of major diameter to minor diameter of said rubber particles before and after annealing at 120° C. for 40 minutes are A
1
and A
2
respectively, and the ratio of A
1
/A
2
ranges form 1.08 to 2.35.
本发明公开了一种透明橡胶改性单亚乙烯基芳香树脂的生产工艺。橡胶改性单亚乙烯基芳香族树脂包括:分散橡胶颗粒(A)和连续相基质共聚物(B)。用表面轮廓仪测量,成型表面的最大高度差(ΔHmax)小于 3,200 Å,平均高度差(ΔHave)小于 2,000 Å。在 120° C 退火 40 分钟前后,所述橡胶颗粒的大直径与小直径的平均比率为 A
1
和 A
2
的比率分别为 A
1
/A
2
为 1.08 至 2.35。
Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A’s zinc endopeptidase
作者:Kateřina Čapková、Mark S. Hixon、Sabine Pellett、Joseph T. Barbieri、Eric A. Johnson、Kim D. Janda
DOI:10.1016/j.bmcl.2009.10.129
日期:2010.1
A series of benzylidene cyclopentenedione-based inhibitors, acting through covalent modi. cation of the active site of botulinum neurotoxin A light chain metalloprotease, are reported. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] OXO-DIHYDROISOINDOLE SULFONAMIDE COMPOUNDS AS MODULATORS OF THE CCK2 RECEPTOR<br/>[FR] COMPOSÉS DE SULFONAMIDE D'OXO-DIHYDROISOINDOLE COMME MODULATEURS DE RÉCEPTEUR CCK2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2008124518A1
公开(公告)日:2008-10-16
[EN] Certain oxo-dihydroisoindote sulfonamide compounds of Formula (I): wherein R1 and R2 are each independently fluoro or chloro; R3 is H or methyl; R4 is chloro or bromo; one of X and Y is a carbonyl and the other is a carbonyl or -CH2-; or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof are CCK2 receptor modulators useful in the treatment of CCK2 receptor-mediated diseases. [FR] Certains composés de sulfonamide d'oxo-dihydroisoindole de formule (I): R1 et R2 sont chacun indépendamment fluoro ou chloro; R3 est H ou méthyle; R4 est chloro ou bromo; soit X soit Y est carbonyle, l'autre étant carbonyle ou -CH2-; Il peut s'agir également d'un sel pharmaceutiquement acceptable, d'un médicament pharmaceutiquement acceptable, ou d'un métabolite pharmaceutiquement actif de ces composés, qui agissent en tant que modulateurs de récepteur CCK2 pour le traitement de maladies dont la médiation est assurée par ce type de récepteur.